[Sunflower]

http://www.ncbi.nlm.nih.gov/pmc/articles...452864.pdf

Regardless of the status of lactoferrin as a wound therapy, a long safety history for lactoferrin has been demonstrated as exemplified by lactoferrin use as a nutritional supplement.

Besides its use as a nutritional supplement, lactoferrin and its antimicrobial peptide derivatives are effective for a number of clinical uses. Lactoferricin therapy is effective against infections of the urinary tract and lactoferrin has been used as an oral treatment for irritable bowel syndrome with a normalizing effect on the gut microbiome (Bellamy et al. 1993; Zagulski et al. 1998; Ha & Kornbluth 2010; Hu et al. 2012; Ochoa et al. 2012).
Intreating systemic or internal infections, lactoferrin and its derivatives have promise in part because these antimicrobial peptides retain efficacy when administered through variousroutes (Brouwer et al. 2011).

Lactoferrin has successfully been utilized in combination with antibacterials for treating mammary gland infections originating from
antibiotic resistant pathogens (Lacasse et al. 2008) and infections with E. coli (Sanchez & Watts 1999; Chen et al. 2004). Clinically, lactoferrin and peptide derivatives have been successfully used in combination with antibiotic resistant Helicobacter pylori and hepatitis C
infections (Kaito et al. 2007; Zullo et al. 2007).

In addition, lactoferrin and its peptide derivatives have been used in combination with antifungal agents against clinically relevant
Candida species in vitro (Wakabayashi et al. 1996; Lupetti et al. 2003; Naidu et al. 2004; Venkatesh & Rong 2008; Harris & Coote 2010).

Lactoferrin has been shown to be synergistically efficacious both in vitro and in vivo in combination with another bioinspired,
anti-biofilm therapy, xylitol (Ammons et al. 2009; Ammons, Ward, Dowd et al. 2011; Ammons,Ward, James 2011).